Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs

Farrukh I.L.; Lachenal N.; Adenov M.M.; Ahmed S.; Algozhin Y.; Coutisson S.; Garavito E.S.; Hewison C.; Holtzman D.; Huerga H.; Janmohamed A.; Khan P.Y.; Jacques G.L.; Lomtadze N.; Melikyan N.; Mitnick C.D.; Mussabekova G.; Osso E.; Perea S.; Putri F.A.; Rashidov M.; Rich M.L.; Sakhabutdinova Y.; Seung K.J.; Stambekova A.; Vásquez D.V.; Franke M.F.; Khan U. · Clinical Infectious Diseases (2024) · DOI: 10.1093/cid/ciad445

Resumen

Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of 31 continued pregnancies, 81% had live births with no reported malformations, and 68% of neonates had normal birth weights. Effective MDR/RR-TB treatment during pregnancy can improve maternal outcomes without harming neonates.